Dean W. Felsher
Publications
- CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med. 2013; (170): 170ra13
- "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget. 2012; (1): 58-66
- Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol. 2012; (2): 188-94
- Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet. 2012; (5): e1002650
- Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A. 2011; (42): 17432-7
- Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med. 2011; (103): 103ra99
- CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 2010; (5): 485-98
- MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010; (4): 301-9
- The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev. 2010; (12): 1281-94
- Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med. 2009; (5): 566-71
- Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet. 2008; (6): e1000090
- Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A. 2007; (32): 13028-33
- Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A. 2006; (44): 16266-71
- Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol. 2004; (11): e332
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004; (7012): 1112-7
- Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer. 2003; (5): 375-80
- Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A. 2003; (17): 9974-9
- Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002; (5578): 102-4
- Characterization of MYC-Induced Tumorigenesis by in Situ Lipid Profiling. Anal Chem. 2013
- In Vivo Imaging-Based Mathematical Modeling Techniques That Enhance the Understanding of Oncogene Addiction in relation to Tumor Growth. Comput Math Methods Med. 2013: 802512
- Noncanonical roles of the immune system in eliciting oncogene addiction. Curr Opin Immunol. 2013; (2): 246-58
- Role of MYCN in retinoblastoma. Lancet Oncol. 2013; (4): 270-1
- Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol. 2013: 91-107
- Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C. BMJ Case Rep. 2012
- HIF-2α suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. Stem Cells. 2012; (8): 1685-95
- High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation. Lab Chip. 2012; (12): 2190-8
- Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J Clin Invest. 2012; (1): 163-77
- SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012; (9): e45119
- STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma. Oncogene. 2012
- Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012; (1): 98-103
- Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One. 2011; (5): e19758
- Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia. 2011; (12): 1882-90
- MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 2011; (6): 2286-97
- Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. J Biol Chem. 2011; (13): 11035-46
- Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood. 2010; (20): 4061-70
- Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res. 2010; (23): 9837-45
- Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals. Int J Radiat Oncol Biol Phys. 2010; (1): 297-305
- Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res. 2010; (19): 4843-52
- Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One. 2010; (6): e11367
- Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther. 2010; (1): 161-70
- MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer. 2010; (6): 597-604
- Myc and a Cdk2 senescence switch. Nat Cell Biol. 2010; (1): 7-9
- Noninvasive molecular imaging of c-Myc activation in living mice. Proc Natl Acad Sci U S A. 2010; (36): 15892-7
- PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. Cancer Res. 2010; (22): 9022-30
- TGFβ-dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas. Cell Cycle. 2010; (23): 4622-6
- Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A. 2009; (11): 4390-5
- Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology. 2009; (2): 471-81
- Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One. 2009; (9): e7172
- SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. Bioconjug Chem. 2009; (4): 742-9
- Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl. 2009; (41): 7668-72
- The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am J Pathol. 2009; (3): 891-7
- Tumor dormancy and oncogene addiction. APMIS. 2008 Jul-Aug; (7-8): 629-37
- (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation. Cancer Biol Ther. 2008; (12): 1947-51
- A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. Mol Cancer. 2008: 74
- An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med. 2008; (9): 979-84
- Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One. 2008; (5): e2125
- Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res. 2008; (13): 5132-42
- Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS One. 2008; (6): e2493
- Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 2008; (9): 3081-6; discussion 3086
- Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch. Lymphat Res Biol. 2008; (3-4): 149-54
- The current STATe of biomarkers to predict the response to anti-angiogenic therapies. Cancer Biol Ther. 2008; (12): 2004-6
- BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res. 2007; (24): 11657-67
- CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet. 2007; (9): 1757-69
- Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther. 2007; (8): 1318-23
- Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. J Immunol. 2007; (7): 4315-21
- HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell. 2007; (3): 230-8
- Identifying critical signaling molecules for the treatment of cancer. Recent Results Cancer Res. 2007: 5-24
- Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood. 2007; (7): 2674-84
- Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. Proc Natl Acad Sci U S A. 2007; (39): 15400-5
- CDK2 is required by MYC to induce apoptosis. Cell Cycle. 2006; (12): 1342-7
- Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol. 2006; (4): 313-7
- MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2. Cell Cycle. 2006; (12): 1348-55
- MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 2006; (13): 6598-605
- Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle. 2006; (16): 1808-11
- c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006; (15): 2096-109
- Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. Oncogene. 2005; (40): 6101-7
- Conditionally MYC: insights from novel transgenic models. Cancer Lett. 2005; (2): 95-9
- Getting at MYC through RAS. Clin Cancer Res. 2005; (12): 4278-81
- Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem. 2005; (42): 35713-22
- Rehabilitation of cancer through oncogene inactivation. Trends Mol Med. 2005; (7): 316-21
- Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res. 2005; (16): 7159-68
- Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res. 2005; (11): 4471-4
- Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol. 2004; (1): 3-11
- Oncogenes as therapeutic targets. Semin Cancer Biol. 2004; (1): 1
- Putting oncogenes into a developmental context. Cancer Biol Ther. 2004; (10): 942-4
- Reversibility of oncogene-induced cancer. Curr Opin Genet Dev. 2004; (1): 37-42
- The E47 transcription factor negatively regulates CD5 expression during thymocyte development. Proc Natl Acad Sci U S A. 2004; (11): 3898-902
- The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004; (39): 14198-203
- How cancers escape their oncogene habit. Cell Cycle. 2003 Jul-Aug; (4): 329-32
- Pharmacological inactivation of MYC for the treatment of cancer. Drug News Perspect. 2003 Jul-Aug; (6): 370-4
- Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 2003; (7): 2797-803
- c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol. 2001; (11): 3789-806
- Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A. 2000; (19): 10544-8
- Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999; (2): 199-207
- Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A. 1999; (7): 3940-4
- A novel octamer regulatory element in the VH11 leader exon of B-1 cells. J Immunol. 1995; (9): 4546-56
- c-myc, MHCI, and NK resistance in immunodeficiency lymphomas. Ann N Y Acad Sci. 1992: 467-9
- Independent rearrangement of Ig lambda genes in tissue culture-derived murine B cell lines. Int Immunol. 1991; (7): 711-8
- A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype. Cancer Res. 1990; (21): 7042-9
- A murine model for B-cell lymphomagenesis in immunocompromised hosts: natural killer cells are an important component of host resistance to premalignant B-cell lines. Cancer Res. 1990; (21): 7050-6
- A rapid method for the purification of monomeric and/or dimeric phospholipases A2 in crotalid snake venoms. Toxicon. 1985; (5): 747-54
Help
Trial Administration